A16 group medicinal products
Original notice title
Estonia – Pharmaceutical products – A16 rühma ravimid
Opportunity Score
Why this score?
Opportunity
0 / 100
Complexity
0 / 100
Risk factors
Submission deadline in 1 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Award Criteria
Lot 1
Lot 2
Lot 3
Buyer
Name
sihtasutus Tartu Ülikooli Kliinikum
Location
Tartu linn, EST
Website
Buyer profile
Identifier
90001478
Activity
Health
Lots (3)
LOT-0001
A16AB03 Alfaagalsidaas
Detailne tehniline kirjeldus on leitav Lisas 1 / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest
Location
Duration
Category
Selection criteria
Award details
LOT-0002
A16AB07 Alfaalglükosidaas
Detailne tehniline kirjeldus on leitav Lisas 1 / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest
Location
Duration
Category
Selection criteria
Award details
LOT-0003
A16AX10 Eliglustaat
Detailne tehniline kirjeldus on leitav Lisas 1 / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest
Location
Duration
Category
Selection criteria
Award details
Procurement Details
- Publication date
- 07 Jun 2026
- Notice type
- Contract notice — standard
- Languages
- Estonian
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 391534-2026
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
0 / 100
Complexity
0 / 100
Risk factors
Submission deadline in 1 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications